Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 273 participants.

Also called NCT03349840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03349840
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Qatar (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03349840. Randomized; no masking; primary purpose treatment. Start 2018-01-07 (actual); primary completion 2018-08-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
Condition
Type2 Diabetes
Intervention (Drug)
Insulin Degludec U100
Intervention (Drug)
Insulin Glargine
Lead sponsor
Weill Cornell Medical College in Qatar (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03349840
Content hash
671e2f8e7782420c730c5f37d8356a056f6f3aa64c607813bcb1a8afbc202970